161 related articles for article (PubMed ID: 38085802)
1. Pancreatic ductal adenocarcinoma staging: A narrative review of radiologic techniques and advances.
Chu LC; Fishman EK
Int J Surg; 2023 Dec; ():. PubMed ID: 38085802
[TBL] [Abstract][Full Text] [Related]
2. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
3. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
[TBL] [Abstract][Full Text] [Related]
4. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
5. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
6. Artificial intelligence for assessment of vascular involvement and tumor resectability on CT in patients with pancreatic cancer.
Bereska JI; Janssen BV; Nio CY; Kop MPM; Kazemier G; Busch OR; Struik F; Marquering HA; Stoker J; Besselink MG; Verpalen IM;
Eur Radiol Exp; 2024 Feb; 8(1):18. PubMed ID: 38342782
[TBL] [Abstract][Full Text] [Related]
7. Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Sulciner ML; Ashley SW; Molina G
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013111
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
[TBL] [Abstract][Full Text] [Related]
9. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy.
van Dam MA; Vuijk FA; Stibbe JA; Houvast RD; Luelmo SAC; Crobach S; Shahbazi Feshtali S; de Geus-Oei LF; Bonsing BA; Sier CFM; Kuppen PJK; Swijnenburg RJ; Windhorst AD; Burggraaf J; Vahrmeijer AL; Mieog JSD
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885196
[TBL] [Abstract][Full Text] [Related]
10. Contemporary management of borderline resectable pancreatic ductal adenocarcinoma.
Lekka K; Tzitzi E; Giakoustidis A; Papadopoulos V; Giakoustidis D
Ann Hepatobiliary Pancreat Surg; 2019 May; 23(2):97-108. PubMed ID: 31225409
[TBL] [Abstract][Full Text] [Related]
11. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
[TBL] [Abstract][Full Text] [Related]
13. Imaging preoperatively for pancreatic adenocarcinoma.
Pietryga JA; Morgan DE
J Gastrointest Oncol; 2015 Aug; 6(4):343-57. PubMed ID: 26261722
[TBL] [Abstract][Full Text] [Related]
14. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma.
Gray S; de Liguori Carino N; Radhakrishna G; Lamarca A; Hubner RA; Valle JW; McNamara MG
Eur J Surg Oncol; 2022 Jun; 48(6):1198-1208. PubMed ID: 35264307
[TBL] [Abstract][Full Text] [Related]
15. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study.
Kim HY; Lee YJ; Chang W; Cho J; Park JH; Lee JC; Kim J; Hwang JH; Kim YH
Eur Radiol; 2022 Jun; 32(6):3799-3807. PubMed ID: 35032213
[TBL] [Abstract][Full Text] [Related]
16. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer.
Scheufele F; Hartmann D; Friess H
Transl Gastroenterol Hepatol; 2019; 4():32. PubMed ID: 31231699
[TBL] [Abstract][Full Text] [Related]
18. How A Patient with Resectable or Borderline Resectable Pancreatic Cancer should Be Treated-A Comprehensive Review.
Kwaśniewska D; Fudalej M; Nurzyński P; Badowska-Kozakiewicz A; Czerw A; Cipora E; Sygit K; Bandurska E; Deptała A
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686551
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]